Skip to content

Clinical trials

Phase 2/3 Attention Deficit Disorder with Hyperactivity trials

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Attention Deficit Disorder with Hyperactivity Phase: Phase 2/3 Clear all

24 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20041
20052
20071
20081
20092
20101
20111
20121
20142
20151
20162
20212
20221
20231
20241
20252

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed17
Recruiting2
Terminated2
Not yet recruiting1
Unknown status1
Withdrawn1

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
Eli Lilly and Company3
New York State Psychiatric Institute3
Massachusetts General Hospital2
Neurocentria, Inc.2
Otsuka Pharmaceutical Co., Ltd.2
Aevi Genomic Medicine, LLC, a Cerecor company1
Alcobra Ltd.1
Ariel University1
Florida International University1
Kieran Cooley1

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Attention Deficit Disorder with Hyperactivity24
Cocaine-Related Disorders2
Autistic Disorder1
Opioid-Related Disorders1

Trials

Showing 26 to 24 of 24. Each trial links to its page on Pharma Observatory.

No trials match these filters.

Try a different keyword, or clear a filter.

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.